GlassScriptPhysician profile
Amir W Raad
NPI 1306446836
$1,932.15
in general payments reported to CMS, 2019-2025
10 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $693 · 2022: $168 · 2023: $369 · 2024: $389 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $481.85 | 2021-2023 | Spravato |
| Abbvie INC. | $383.21 | 2024-2025 | |
| Alkermes, INC. | $312.35 | 2021-2022 | |
| Phadia US INC. | $136.38 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.94 | 2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $120.57 | 2024 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $107.24 | 2021 | |
| Horizon Therapeutics Plc | $96.56 | 2022 | |
| Neurocrine Biosciences, INC. | $95.87 | 2021 | |
| Axsome Therapeutics, INC. | $65.18 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Raad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.